Quotes 5-day view Delayed Nasdaq
10/26/2020
10/27/2020
10/28/2020
10/29/2020
10/30/2020
Date
207.15(c)
212.19(c)
208.34(c)
207.01(c)
208.36(c)
Last
2 087 483
2 756 330
2 221 370
1 931 045
2 828 791
Volume
-2.09% +2.43% -1.81% -0.64% +0.65% Change
Sales 2020
6 143 M - -
Net income 2020
2 661 M - -
Net cash position 2020
6 120 M - -
P/E ratio 2020
20,7x
Yield 2020
-
Sales 2021
6 926 M - -
Net income 2021
2 675 M - -
Net cash position 2021
9 316 M - -
P/E ratio 2021
20,7x
Yield 2021
-
Capitalization
54 210 M 54 210 M -
EV / Sales 2020
7,83x
EV / Sales 2021
6,48x
Nbr of Employees
3 000
Free-Float
72,2%
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows:
- income from sales of products (99.9%);
- royalties and income from partnership, research, and development agreements (0.1%).
Net sales break down geographically as follows:...
Notations Surperformance© of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
All news about VERTEX PHARMACEUTICALS
News in other languages on VERTEX PHARMACEUTICALS
Chart VERTEX PHARMACEUTICALS
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends VERTEX PHARMACEUTICALS
Short Term Mid-Term Long Term Trends Bearish Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
26
Average target price
289,71 $
Last Close Price
208,36 $
Spread / Highest target
71,3%
Spread / Average Target
39,0%
Spread / Lowest Target
5,59%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
